Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing.

Useful resources referenced in this podcast:

March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022)

https://www.canadianhealthpolicy.com/product/patented-medicines-expenditure-in-canada-1990-2022-8th-edition/

January 2024 – Conference Board of Canada (Patented Medicines Expenditure in Canada 1990–2022 8TH Edition)

https://www.conferenceboard.ca/wp-content/uploads/2022/10/access-and-time-to-patient_jan2024.pdf

Innovative Medicines Canada – Access to Medicine

https://innovativemedicines.ca/browse-by/access-to-medicine/

April 2023 – Canadian Health Policy Journal (New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage)

https://www.canadianhealthpolicy.com/wp-content/uploads/2022/01/SKINNER-APR-23-New-cancer-drugs-in-Canada-2012-to-2021-final-1.pdf

April 2022 – Canadian Health Policy Institute (Access to New Medicines in Canada 2016 – 2021)

https://www.canadianhealthpolicy.com/posts/access-to-new-medicines-in-canada-2016-2021-federal-provincial-public-drug-programs-and-private-sector-drug-plans/

The opinions shared in this podcast are Sam’s own views and not representative of the company he is working for.

In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role.

Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access.

The opinions shared in this episode are Joao's own views and not representative of the company he is working for.

In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations.
Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access to help them define and communicate patient value.
The discussion also explores the role of AI for HEOR and market access teams and what's on the horizon that leaders should prepare for.

The opinions shared in this episode are Becky's own views.